Acute Endophthalmitis Following Intravitreal Triamcinolone Acetonide Injection
Overview
Authors
Affiliations
Purpose: To report the clinical features, causative organisms, management, and visual acuity outcomes of eight eyes of eight patients who developed acute postoperative endophthalmitis following intravitreal injection of triamcinolone acetonide (IVTA).
Design: Retrospective, multicenter, interventional, case series.
Methods: A retrospective, interventional, case series of all patients with acute postoperative endophthalmitis following IVTA at seven academic clinical centers between March 2001 and July 2002.
Results: A total of 922 IVTAs were performed. Eight eyes of eight patients with acute postoperative endophthalmitis were identified in the 6 weeks following IVTA for an incidence of 0.87% (95% confidence interval of 0.38% to 1.70%). The median time to presentation was 7.5 days (range, 1-15 days) after IVTA. The most common clinical findings were iritis (n = 8), vitritis (n = 8), hypopyon (n = 8), pain (n = 7), red eye (n = 6), and decreased vision (n = 5). The median presenting visual acuity was 20/1127 (range, 20/60 to light perception). Initial treatment consisted of vitreous tap and injection of antibiotics (n = 6) or pars plana vitrectomy and injection of intravitreal antibiotics (n = 2). Intraocular cultures yielded identification in seven patients. One demonstrated intracellular gram-positive cocci in chains with numerous polymorphonuclear cells on gram stain. The median postinfection vision was 20/400 (range, 20/40 to no light perception). Three patients ended up with no light perception visual acuity, including enucleation (n = 1) and phthisis (n = 1).
Conclusions: Acute postoperative endophthalmitis following IVTA occurs rapidly and can result in severe loss of vision.
Oleogels: Versatile Novel Semi-Solid System for Pharmaceuticals.
Pawar V, Dessai A, Nayak U AAPS PharmSciTech. 2024; 25(6):146.
PMID: 38937416 DOI: 10.1208/s12249-024-02854-2.
Alacamli G Arq Bras Oftalmol. 2023; 87(1):0245.
PMID: 38088670 PMC: 11587502. DOI: 10.5935/0004-2749.2023-0245.
Kim Y, Hyun C, Lee M Medicine (Baltimore). 2023; 102(31):e34576.
PMID: 37543803 PMC: 10402935. DOI: 10.1097/MD.0000000000034576.
Lee J, Jo Y, Lee J PLoS One. 2022; 17(12):e0278625.
PMID: 36454919 PMC: 9714883. DOI: 10.1371/journal.pone.0278625.
Qin W, Qin X, Li L, Gao Y Front Mol Biosci. 2022; 9:831632.
PMID: 35274006 PMC: 8901606. DOI: 10.3389/fmolb.2022.831632.